Metabolic Brain Disease· 2025Q2· Review
“Rewiring brain immunity: targeting microglial metabolism for neuroprotection in neurodegenerative disorders”
- 60citations
- Q2SCImago
- 2025year
Short summary
Microglial metabolic reprogramming, shifting from glycolysis (pro-inflammatory) to oxidative phosphorylation (anti-inflammatory), offers a novel therapeutic target for neurodegenerative diseases.
AI-generated from the title and abstract; the full text is not read.
Key points
- Microglial metabolic phenotypes (glycolytic vs. oxidative phosphorylation) are key drivers of neuroinflammation in neurodegenerative disorders.
- Metabolic sensors (AMPK, mTOR, HIF-1α) control microglial repolarization in response to disease pathologies.
- Therapeutic strategies include pharmacological agents (metformin, rapamycin), ketogenic diets, and gut microbiota modulation.
- Targeting microglial metabolism offers a new avenue for neuroprotection and disease modification in Alzheimer's, Parkinson's, MS, stroke, and TBI.
AI-generated from the title and abstract; the full text is not read.
Abstract
Neuroinflammation, a pervasive hallmark in many neurological and neuropsychiatric diseases, is largely dictated by the functional phenotypic dynamics of microglia, the immune system of the brain. Recent data illustrate that these phenotypic changes, from neuroprotective scavenging to neurotoxic pro-inflammatory effects, are intrinsically regulated by microglial metabolic repolarization. This review synthesizes understanding of discrete microglial metabolic phenotypes like the glycolytic reliance of pro-inflammatory (M1-like) microglia and the oxidative phosphorylation/fatty acid oxidation bias of anti-inflammatory/resolving (M2-like) microglia. We discuss how central metabolic sensors like AMPK, mTOR, and HIF-1α oversee these metabolic shifts in response to disease-targeted pathologies in Alzheimer's, Parkinson's, Multiple Sclerosis, ischemic stroke, and traumatic brain injury. Moreover, we review innovative therapeutic strategies directed toward microglial metabolism, involving pharmacological modulators (e.g., metformin, rapamycin, and ketone bodies), nutritional interventions (e.g., ketogenic diets), and modulation of gut microbiota. By tightly specific re-tuning of microglial cells' bioenergetics, these approaches enable unprecedented opportunities to counteract neuroinflammation, enhance pathological clearance, and induce neuroprotection, paving the way for a new generation of disease-modifying therapies of neurodegenerative disorders.
The authors' abstract, as published at the source. Metabolic Brain Disease, 2025 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Neurology (Neuroscience)
NeurologyNeuroscience